Waters Corporation

The forensic screens point in different directions and should be read separately. The Beneish M-Score for 2025 is -2.369, which is below the -1.78 threshold and outside the elevated manipulation-risk zone. This is a screening result: it means the model did not flag the reported numbers, not that they have been verified. The Altman Z″-Score is 10.00, inside the safe zone of 2.60 or above. That reading is based on the balance sheet at December 31, 2025, before the BDS Business Acquisition added substantial debt and goodwill, so it does not capture the post-closing position. The Piotroski F-Score is 6 of 8 computable signals, a count of the checklist items the data could evaluate for 2025. Operating cash flow of $652.55 million against net income of $642.63 million gives a ratio of 1.02, meaning 2025 cash generation roughly matched reported earnings, although cash flow itself declined from 2024. The business itself centers on liquid chromatography and mass spectrometry systems, columns, consumables and post-warranty service plans, plus the TA Instruments thermal analysis line. Nine-month 2025 figures from the 10-Q show net income of $417.4 million against $406.4 million a year earlier, but operating cash flow of $488.0 million against $522.0 million. Long-term debt fell from $1.63 billion at year-end 2024 to $947.45 million at year-end 2025, and equity rose from $1.83 billion to $2.56 billion. Those balance sheet moves predate the deal, so they do not show the leverage the company took on in February 2026.

Catalyst.Revenue for 2025 was $3.17 billion, up 7.0% from $2.96 billion in 2024, and net income was $642.63 million compared with $637.83 million. The larger development in the filings is the February 9, 2026 closing of the BD Biosciences and Diagnostic Solutions acquisition, which Waters describes as transformative. The deal was structured as a Reverse Morris Trust, leaving Becton, Dickinson's shareholders with about 39.2% of the combined company and existing Waters shareholders with about 60.8%. Management has reorganized the business into four new segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences.

Hidden risk.The main tension is between the reported 2025 year-end figures and the deal that followed. Total assets at December 31, 2025 were $5.08 billion, while the acquisition carried a total purchase price, including assumed debt, of $16.8 billion. Waters also assumed roughly $4.0 billion of new debt that SpinCo incurred to fund a cash distribution to BD. Meanwhile, 2025 operating income fell to $802.59 million from $826.35 million, and operating cash flow fell to $652.55 million from $762.12 million, a decline of about 14.4%. The risk-factor excerpt supplied here contains financial statements rather than risk discussion, so readers may want to look at the full Item 1A for integration and leverage details.